The Saudi Mouth — Part 3: The Lesion You Should Not Miss

Oral cancer carries a 50% five-year survival rate when caught late — yet only 37% of Arab dentists perform routine screening. Here is what the evidence says, and what it asks of every clinician.

Research

Oral Cancer Screening and Why It Belongs in Every Saudi Dental Visit

There is a procedure that takes less than two minutes, requires no equipment, costs nothing, and has the potential to save a patient's life.

Most dentists know how to do it. Far fewer actually do it — consistently, systematically, at every recall visit.

That gap is the subject of Part 3 of The Saudi Mouth.

Oral cancer screening is not a specialty intervention. It is not the exclusive domain of oral medicine consultants or maxillofacial surgeons. It is a basic clinical responsibility that belongs to every dental professional who examines a patient's mouth — which is every dental professional, at every appointment. The evidence on what routine screening can achieve, and what its absence costs, is not ambiguous.

The Numbers That Frame the Problem

Oral cancer kills approximately half the people it is diagnosed in.

The global five-year overall survival rate for oral cancer remains at 50 to 60%, despite decades of treatment advances.¹ That figure has not moved meaningfully in forty years. The reason is not a failure of oncology. It is a failure of timing.

When oral cancer is caught at Stage I or II — while the lesion is small, localized, and has not spread to lymph nodes or distant sites — five-year survival exceeds 80%.² When it is diagnosed at Stage III or IV — which is when most cases are actually found — survival drops to approximately 38%.²

The difference between those two outcomes is not treatment. It is detection.

And detection is a dental problem, not an oncology problem — because the mouth is where the lesion lives, and the dental chair is where patients present before symptoms are severe enough to drive them to a physician. By the time a patient notices a persistent ulcer, a painless white patch, or unilateral cervical lymphadenopathy and seeks medical care, the lesion has often been present — and growing — for months.

In Southern Saudi Arabia, incidence rates of oral cancer reach up to 10 per 100,000 people.³ A 2025 BMC Oral Health study found Saudi Arabia's age-standardized oral cancer incidence rate at 8.4 per 100,000 — among the highest in the region.⁴ National head and neck cancer data show the mean age-standardized rate across Saudi regions at 3.68 per 100,000, with Jazan recording 5.3 per 100,000.⁵

These are not negligible numbers. They represent real patients, presenting to dental practices across the country, whose lesions may already be in the room.

What the Screening Data Shows — and Does Not Show

A landmark 2025 study published in JAMA Network Open examined oral cancer awareness across 13 Middle Eastern and North African countries. The findings were unambiguous: only 37.2% of the public could identify risk factors for oral cancer, 48.4% could recognize symptoms, and 59.1% were aware that regular dental check-ups offered a protective benefit.⁶

These are public awareness figures. The clinical screening data is, if anything, more concerning.

A 2025 study published in the Journal of the Egyptian National Cancer Institute examined oral cancer awareness and screening practices among Arab dentists. Only 37% of participating dentists carried out proper clinical screening for oral cancer, and only 31% performed routine lymph node examinations.⁷

Read those together: less than four in ten dentists in the Arab world are conducting proper oral cancer screening at each patient visit. Less than a third are examining cervical lymph nodes — one of the most critical indicators of disease spread.

Knowledge is not the limiting factor. Most dentists know what oral cancer looks like and understand the risk factors. The gap is in the translation of that knowledge into a systematic, non-negotiable clinical habit.

Who Is at Risk in the Saudi Context

Globally, tobacco and alcohol account for approximately 75% of oral cavity squamous cell carcinoma cases.⁸ In Saudi Arabia, the risk profile looks different — alcohol is not a significant contributor, but the tobacco picture is complex and underweighted in clinical history-taking.

Waterpipe smoking. As detailed in Part 2 of this series, waterpipe users carry a 5.1-fold increased periodontal risk and documented cytotoxic and genotoxic changes in oral mucosal cells.⁹ A 2023 systematic review confirmed epithelial dysplasia and DNA methylation alterations across 20 studies of waterpipe smokers.¹⁰ These patients need soft tissue examination at every visit.

Smokeless tobacco (Shamma, Toombak, Naswar). Prevalent in specific Saudi regions — particularly the southern provinces — and strongly associated with oral submucous fibrosis, leukoplakia, and squamous cell carcinoma. These products are often not captured in a standard tobacco history question.

Areca nut / Betel quid use. Present in migrant worker communities from South and Southeast Asia, betel quid chewing is one of the most potent known risk factors for oral submucous fibrosis and oral cancer. The clinical presentation — limited mouth opening, blanching of the buccal mucosa, burning sensation — is distinctive but requires knowledge to recognize.

Age and immune status. Oral cancer incidence rises significantly after age 40. Patients on immunosuppressive therapy carry elevated mucosal risk.

HPV. High-risk HPV (particularly HPV-16 and 18) accounts for 15 to 25% of oropharyngeal cancers globally.⁸ These lesions may not present with classic leukoplakia or erythema and require systematic posterior oral and oropharyngeal examination.

The Examination Itself

Oral cancer screening is a visual and tactile examination of the oral mucosa. It requires no equipment beyond adequate lighting and gauze. The full sequence takes under two minutes.

  1. Extra-oral: Inspect and palpate cervical lymph nodes. Note any asymmetry, firmness, or fixation.
  2. Lips: Examine vermilion border, labial mucosa, and commissures.
  3. Buccal mucosa and vestibule: Bilateral examination including the retromolar pads.
  4. Gingiva and alveolar ridges: Edentulous areas carry higher risk.
  5. Tongue: Ask the patient to extend the tongue, then use gauze to retract it laterally — the lateral borders are the most common site of oral squamous cell carcinoma.
  6. Floor of mouth: Ask the patient to lift the tongue to the palate.
  7. Hard and soft palate: Inspect with adequate light, including the oropharyngeal aperture.

Any lesion that is white, red, or mixed; non-healing after two weeks; firm or indurated on palpation; painless; or associated with cervical lymphadenopathy requires urgent referral for biopsy and specialist evaluation.

The clinician's job is to find it. The histopathologist's job is to characterize it.

The Referral Threshold

One of the most consistent barriers to early detection is clinician hesitation — the reluctance to alarm a patient or trigger a referral that may turn out to be unnecessary.

This calculation is wrong.

The cost of an unnecessary biopsy referral is inconvenience. The cost of a missed Stage I carcinoma presenting two years later as a Stage IV lesion is a patient's life — or a significant reduction in it.

The referral threshold for oral mucosal lesions that do not resolve within two weeks should be low and consistent. Document the lesion, photograph it if possible, and refer. That is the entire decision tree.

What Systematic Screening Looks Like in Practice

The practices with the highest early detection rates are not the ones with the most specialized equipment. They are the ones where the soft tissue examination is part of the intake protocol — documented, consistent, and non-negotiable.

Five things that make oral cancer screening systematic:

  1. Add it to the medical history intake form. "Do you use any form of tobacco — cigarettes, waterpipe, or smokeless tobacco?" alongside "Any mouth sores that have not healed in two weeks?"
  2. Include soft tissue examination findings in every clinical note.
  3. Brief clinical staff to flag any patient who mentions a persistent sore.
  4. Establish a defined two-week review protocol for suspicious lesions — not indefinite watchful waiting.
  5. Refer rather than monitor. The GP's role is detection and referral, not long-term surveillance of lesions of uncertain behavior.

A Note on Patient Communication

Most patients in Saudi Arabia have not been told that their dentist screens for cancer during a routine check-up. The 2025 JAMA Network Open study found fewer than 60% of people in the MENA region were even aware that dental visits could play a protective role in oral cancer.⁶

Telling a patient at the start of an examination — "I'm also going to check your soft tissues as part of the routine" — takes five seconds. It communicates value beyond teeth. It creates the conditions for patients to disclose the lesion they dismissed as insignificant.

The dentist who normalizes this conversation is the one whose patients come back to report the sore that has been there for three weeks.

Key Takeaways

  1. Oral cancer carries a 50–60% five-year survival rate globally. Detection at Stage I–II improves survival to over 80%; late-stage diagnosis drops it to approximately 38%.
  2. Saudi Arabia's oral cancer incidence reaches 8.4 per 100,000 (national age-standardized rate) — among the highest in the Middle East. Southern regions reach up to 10 per 100,000.
  3. Only 37% of Arab dentists perform proper oral cancer screening. Only 31% examine cervical lymph nodes routinely.
  4. The Saudi risk profile includes waterpipe smoking, smokeless tobacco (Shamma, Naswar), areca nut use, and HPV — all missed by a single "do you smoke cigarettes?" question.
  5. The full soft tissue examination takes under two minutes. It belongs at every recall visit, for every patient.
  6. The referral threshold for non-healing lesions should be low, consistent, and applied within two weeks.

References

  1. Global 5-year oral cancer survival rate 50–60%. The Lancet Oncology. 2025. The Lancet Oncology — Oral Cancer Survival00708-9/fulltext)
  2. Stage I/II vs. Stage III/IV survival data. Early Detection of Oral Cancer — Review. https://fds.uniq.edu.iq/storage/publication_folder/file/01KH3S3CZQ7AGTDBM27BR7QRYQ.pdf
  3. Oral cancer incidence up to 10/100,000 in Southern Saudi Arabia. KAIMRC Innovations. https://innovations.kaimrc.med.sa/en/research/49/oral-cancer-in-the-arab-world.html
  4. Saudi Arabia age-standardized oral cancer incidence rate 8.4/100,000. BMC Oral Health. 2025. https://link.springer.com/article/10.1186/s12903-024-05266-7
  5. Head and neck cancer trends in Saudi Arabia. Journal of Oral and Maxillofacial Surgery. https://www.jocms.org/index.php/jcms/article/view/1664
  6. Public awareness and knowledge of oral cancer in 13 MENA countries. JAMA Network Open. 2025. PMID: 40048163. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831078
  7. Oral cancer awareness among Arab dentists. Journal of the Egyptian National Cancer Institute. 2025. https://link.springer.com/article/10.1186/s43046-025-00290-2
  8. HPV and tobacco as primary risk factors. International Dental Journal. 2025. PMID: 39922763. https://pmc.ncbi.nlm.nih.gov/articles/PMC12142758/
  9. Al-Zahrani MS et al. Tobacco smoking and periodontal health in a Saudi population. Journal of Periodontology. 2006. PMID: 16274311. https://pubmed.ncbi.nlm.nih.gov/16274311/
  10. Grillo R et al. Cytotoxic and genotoxic effects of waterpipe on oral mucosal cells. Sultan Qaboos University Medical Journal. 2023. PMID: 36865434. https://pmc.ncbi.nlm.nih.gov/articles/PMC9974039/

The Saudi Mouth is a SaudiDent original series by Dr. Mahmoud H. Al-Johani. Part 1 — Our Children's Teeth: https://saudident.com/blog/our-childrens-teeth-dental-caries-saudi-arabia Part 2 — The Shisha Session: https://saudident.com/blog/the-saudi-mouth-shisha-waterpipe-oral-health

Read on SaudiDent